New tests launched in April
In April 2023, Mayo Clinic Laboratories announced 10 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in April 2023 by Mayo Clinic Laboratories:
Diagnosis of pheochromocytoma and paraganglioma, as an auxiliary test to fractionated plasma and urine metanephrine measurements (plasma metanephrine is the preferred test for this diagnosis).
Diagnosis and follow-up of patients with neuroblastoma and related tumors, as an auxiliary test to urine vanillylmandelic acid and homovanillic acid measurements.
Evaluation of patients with autonomic dysfunction or failure or autonomic neuropathy.
FBCFS | Barbiturates Confirmation, Serum
Biochemical diagnosis and monitoring of intestinal carcinoid syndrome using a plasma specimen.
Evaluating patients with suspected paraneoplastic encephalitides using spinal fluid specimens.
MA2ES | Ma2 Antibody by ELISA, Serum
Evaluating patients with suspected paraneoplastic encephalitides using serum specimens.
SC018 | Whole Blood
An aid in the diagnosis of alveolar soft-part sarcoma or renal cell carcinoma variant when used in conjunction with an anatomic pathology consultation.
Evaluating patients suspected of having rheumatoid arthritis (RA).
Differentiating RA from other inflammatory arthritis or connective tissue diseases.
Diagnosis and stratification of rheumatoid arthritis.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories: